Faricimab lacks proof of added benefit over comparator therapies for macular edema
Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion.
Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion. Th...
Read More
Other Stories in Health
- Why Are Cancers So Freaky? What To Know About This Zodiac Sign
- People seek NHS advice on drinking and breastfeeding at Christmas
- Raw milk may carry hidden risks of flu transmission
- Polluted Air Quality And Eye Care: Practical Steps To Prevent Vision Damage
- Nutrition progress stalls: Most nations lag behind 2030 goals
- Route to Christmas: Day 13 2024
- New advisory offers evidence-based strategies to prevent postoperative delirium in older adults
- Wheat flour or Ragi flour: Which one is healthier?
- Keynote Selena Gomez spotlights prioritizing mental health during Academy Women's Luncheon
.png)
